IZI. O. Zayats

I. O. Zayats

*This is an algorithmically generated author record based on publicly available information.

I. O. Zayats has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    THE ROLE OF ANEMIA IN THE DEVELOPMENT OF NON-FATAL CARDIOVASCULAR EVENTS AND PREDICTION OF THEIR RISK IN PATIENTS WITH CORONARY HEART DISEASE

    by I.O. Zaiats, O.O. Khanyukov

    РОЛЬ АНЕМІЇ В РОЗВИТКУ НЕФАТАЛЬНИХ СЕРЦЕВО-СУДИННИХ ПОДІЙ ТА ПРОГНОЗУВАННЯ РИЗИКУ ЇХ ВИНИКНЕННЯ У ПАЦІЄНТІВ З ІШЕМІЧНОЮ ХВОРОБОЮ СЕРЦЯ O.O. Ханюков1, I.O. Заяць2 1Дніпровський державний медичний університет, кафедра внутрішньої медицини 3, м. Дніпро, Україна, ORCID: 0000-0003-4146-0110, е-mail: khanyukov.al@gmail.com; 2Європейський медичний університет, кафедра внутрішньої медицини, м. Дніпро, Україна, ORCID: 0000-0001-8225-5901, е-mail: irinazayats8gb@gmail.com Резюме. Мета дослідження: вивчити вплив залізодефіцитної анемії (ЗДА) на ризик розвитку нефатальних серцево-судинних подій (ГІМ, прогресії стенокардії напруги та хронічної серцевої недостатності, виникнення тахіаритмій) у пацієнтів з ІХС; розробити математичні моделі оцінки ризику розвитку нефатальних ускладнень (ГІМ і прогресії хронічної серцевої недостатності) у хворих на ІХС, в залежності від рівню гемоглобіну. Методи. В дослідженні брали участь 95 хворих на ІХС, які перебували на стаціонарному лікуванні в терапевтичних та кардіологічних відділеннях ЛПУ міста Дніпро. Основну групу склали 53 хворих з супутньою анемією, контрольну – 42 пацієнти без анемії. З метою виявлення нефатальних ускладнень ІХС (ГІМ, декомпенсації СН, аритмії) і з’ясування причин їх виникнення, у пацієнтів обох груп ретроспективно проведено 8-річний аналіз медичної документації, з наступним кореляційним аналізом та визначенням факторів, які сприяють розвитку нефатальних серцево-судинних подій, і розробкою математичної моделі ризику ймовірних ускладнень впродовж 5-8 років. Результати. Отримані статистично значущі показники несприятливого впливу анемії на виникнення кардіо-васкулярних подій (прогресії ішемії міокарду, серцевої недостатності, тахіаритмій) (р 0,43 (Se = 87,8%, Sp = 87,0%, De = 87,4%). Ключові слова: ішемічна хвороба серця, серцево-судинні ускладнення, хронічна серцева недостатність, анемія, прогнозування.

  • Open Access

    Influence of L-Arginine on the Clinical Course and Hemodynamic Parameters in Patients with Coronary Artery Disease on the Background of Anemic Syndrome in Middle-Aged and Older Patients

    by O. O. Khanyukov, I. O. Zayats

    The purpose of the study was to evaluate hemodynamic changes in middle-aged and older patients with coronary artery disease and anemia, against the background of standard therapy, as well as in combination with L-arginine. Materials and methods. 53 patients (35 women and 18 men) with stable ischemic heart disease and mild to moderate anemia (mean age 73.1 ± 1.2 years old) were examined. Among them, there were 24 (45.3%) patients with HF I, 21 (39.6%) patients with HF 2A, and 8 (15.1%) patients with HF 2B. The control subgroup (subgroup 1) consisted of 24 patients who received standard therapy for coronary artery disease and anemia. The remaining 29 people, in addition to standard therapy, additionally received L-arginine according to the scheme and made up the 2nd subgroup of the study. The follow-up period for patients was 6 months. An anamnesis was collected from all patients, the clinical picture of the disease was assessed, blood pressure and heart rate were measured, clinical and biochemical blood tests were studied, ECG and ECHO-CG were recorded. The effect of treatment with iron preparations was assessed by the dynamics of iron metabolism parameters. In the course of the ECHO-CG study, the main structural-geometric and functional parameters of the left ventricle were determined. Results and discussion. Under the influence of standard therapy and an increase in hemoglobin levels to normal levels (from 114.8 ± 1.4 g/l to 131.9 ± 1.1 g/l in the first subgroup; from 112.3 ± 2.1 g/l to 140.0 ± 1.3 g/l in the second subgroup (p<0.001 between subgroups after treatment) [17], complaints of general weakness, shortness of breath and palpitations decreased and the general condition of patients improved (blood pressure, heart rate, respiratory rate parameters normalized; there was a decrease or elimination of edema) in both clinical groups. But in patients who additionally received L-arginine, the intensity of manifestations of general weakness and palpitations were significantly less (p<0.001 and p<0.05 between subgroups). Against the background of standard therapy, symptoms such as dyspnea, edema, and pain in the heart area also decreased in both subgroups, but the effect of L-arginine on these symptoms was more noticeable. According to the results of the ECHO-CG study, in patients with coronary artery disease and anemia, a statistically significant recovery of structural and geometric parameters of the myocardium was observed: a decrease in end-diastolic and end-systolic volume and an increase in myocardial contractility in both subgroups, however, against the background of additional intake of L-arginine, the dynamics of indicators was more expressed; regression of signs of left ventricle hypertrophy. Conclusion. The results of the study showed the positive effect of L-arginine on cardiac remodeling and the clinical condition of middle-aged and older patients. Treatment with L-arginine did not cause side effects and did not require discontinuation of the drug

  • Open Access

    Influence of Nitric Oxide Donors on the Clinical Course of Coronary Heart Disease with Concomitant Anemia

    by O. O. Khanyukov, I. O. Zayats

    The purpose of the study was to evaluate the effect of L-arginine on the general condition of patients with coronary artery disease and anemia, on the dynamics of laboratory parameters of iron metabolism, glucose, high-sensitivity C-reactive protein, lipid metabolism and the functional state of the kidneys in particular category of patients. Materials and methods. The study involved 53 patients with coronary heart disease and anemia, aged from 56 to 85 years. The patients were randomized into two groups. The control group included 24 patients who received standard therapy for coronary heart disease and anemia. The main group included 29 patients who, in addition to standard therapy, received L-arginine intravenously and orally according to the scheme. Results and discussion. As a result of treatment, red blood counts and iron metabolism in the main and control groups normalized. A comparative analysis of iron metabolism indicators showed that during treatment, patients who received L-arginine had a more active metabolism and accumulation of iron in the body. Restoration of hemoglobin levels in patients with coronary heart disease and anemia contributed to the improvement of the general condition and well-being in both groups. But general weakness (p<0.001) and palpitations (p<0.05) after treatment were less pronounced in the main group. Observations showed the dynamics of high-sensitivity C-reactive protein, indicators of lipid metabolism and the functional state of the kidneys in the main and control groups. A significant decrease in lipidogram parameters after treatment was noted both in patients of the control and the main group; but due to the addition of L-arginine, changes in total cholesterol, high density lipoprotein and atherogenic index in the main group compared with the control group were more pronounced (from p<0.01 to p<0.001). The inclusion of statins in the standard therapy contributed to a significant decrease in the levels of high-sensitivity C-reactive protein in patients in the main group – 17.8% (p<0.001) and 11.4% (p<0.05) in the control group. Conclusion. According to the results of the study, it was found that nitric oxide donors have a beneficial effect on iron metabolism, lipid profile, high-sensitivity C-reactive protein level, the functional state of the kidneys, and, probably, on the degree of heart failure. It has been established that against the background of treatment with L-arginine, the bioavailability of orally incoming iron increases; the supply of iron in the body increases significantly; there was a trend towards normalization of lipid profile and functional state of the kidneys with significant changes in creatinine and glomerular filtration rate levels; decrease in signs of heart failure (general weakness, palpitations)


  • Open Access

    Changes of Rat Embryon Nephrogenesis during Cadmium Salt Intoxication in Pregnant Females

    by V. F. Shatorna, N. M. Tereshchenko, V. O. Sorokin, M. K. Kravchenko, I. I. Samoilenko, O. Yu. Yakutovich, I. O. Zayats

    The purpose of the experimental study was to determine morphogenetic disorders of embryonic and fetal kidney development in chronic intragastric exposure to cadmium salts (cadmium chloride, cadmium citrate) in pregnant females. Materials and methods. Low doses of cadmium salts were selected for the study, which can be compared with the actual concentration of cadmium in the daily diets of women, including pregnant women, in industrial regions. In the experiment, female rats with a given gestational age were divided into groups as follows: Group 1 – control (number of females – n = 16, of which 8 left the experiment on the 13th day of pregnancy, and 8 on the 20th; the number of embryos – n13 = 76; n20 = 77); Group 2 – administration of cadmium chloride at a dose of 1.0 mg/kg body weight of the female (number of females – n = 16; number of embryos – n13 = 65; n20 = 62); Group 3 – administration of cadmium citrate at a dose of 1.0 mg/kg body weight of the female (number of females – n = 16; number of embryos – n13 = 69; n20 = 70). Results and discussion. New quantitative data on the effect of cadmium salts were obtained on the thickness of the cortical and cerebral layers of the kidneys, the diameter and area of the cavity of the nephron capsule in the prenatal period of development in chronic female intoxication. On the 13th day, the effect of cadmium salts on the development of embryonic kidneys was multidirectional: the effect of cadmium chloride led to an increase in the thickness of the mesonephros and mesonephric duct, and the effect of cadmium citrate reduced the studied parameters. On the 20th day of rat embryogenesis in the group exposed to cadmium chloride, the renal weights increased, and when exposed to cadmium citrate, the weight of the kidneys decreased significantly (p˂0.05) both in comparison with control values and in the group exposed to cadmium chloride. On the 20th day of development, in order to exclude an error in estimating the dynamics of changes in the weight of embryo mass and kidney mass, the nephrofetal index was calculated, i.e. the ratio of wet kidney mass to wet weight of fixed fetus. Histological parameters of nephron diameters were also compared. Conclusion. Cadmium citrate has been shown for the first time to be less non-photoxic than cadmium chloride. Calculation of the area of the cavity of the nephron capsule by the spline contour method showed a 2.6-fold decrease in the average area of the capsule cavity in the group exposed to cadmium chloride relative to the control mean values, indicating a violation of nephrogenesis. When exposed to cadmium citrate, there was also a decrease in the area of the cavity of the nephron capsule by 1.8 times, which indicates a lower level of nephrotoxic cadmium citrate compared to cadmium chloride, despite the identity of the dose of exposure